Next Article in Journal
Correlation of Influenza B Haemagglutination Inhibiton, Single-Radial Haemolysis and Pseudotype-Based Microneutralisation Assays for Immunogenicity Testing of Seasonal Vaccines
Previous Article in Journal
Immunogenicity and Protective Activity of Pigeon Circovirus Recombinant Capsid Protein Virus-Like Particles (PiCV rCap-VLPs) in Pigeons (Columba livia) Experimentally Infected with PiCV
Previous Article in Special Issue
Safety of Newer Disease Modifying Therapies in Multiple Sclerosis
Review

Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies

by 1,2,3,* and 4
1
Department of Neurology, Landesklinikum Mistelbach-Gänserndorf, 2130 Mistelbach, Austria
2
Department of Neurology, Klinikum rechts der Isar, Technische Universität München, 81675 München, Germany
3
Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical University, 5020 Salzburg, Austria
4
Department of Neurology, Medical University of Vienna, 1090 Vienna, Austria
*
Author to whom correspondence should be addressed.
Academic Editor: Vasso Apostolopoulos
Received: 6 January 2021 / Revised: 18 January 2021 / Accepted: 25 January 2021 / Published: 28 January 2021
(This article belongs to the Special Issue Multiple Sclerosis and Its Complications: Clinical Trials)
Several concerns have been raised about the use of immunodepleting agents including alemtuzumab, cladribine and CD20-depleting antibodies in people with multiple sclerosis (pwMS) during the coronavirus disease (COVID) 2019 pandemic. As the end of the pandemic is not yet in sight, vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) may be an elegant strategy to overcome the potential hazards associated with initiating and continuing treatment with immune-depleting agents. In this review, we summarize the immunological effects of immune-depleting therapy and underlying considerations for the hitherto existing recommendations that suggest a restricted use of immune-deleting therapies during the pandemic. Moreover, we critically discuss open questions regarding vaccination in general and against SARS-CoV-2 in pwMS. View Full-Text
Keywords: vaccination; COVID-19; SARS-CoV-2; multiple sclerosis; disease-modifying drugs; immune-depleting therapies; CD20 depletion; cladribine; alemtuzumab vaccination; COVID-19; SARS-CoV-2; multiple sclerosis; disease-modifying drugs; immune-depleting therapies; CD20 depletion; cladribine; alemtuzumab
Show Figures

Figure 1

MDPI and ACS Style

Sellner, J.; Rommer, P.S. Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies. Vaccines 2021, 9, 99. https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines9020099

AMA Style

Sellner J, Rommer PS. Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies. Vaccines. 2021; 9(2):99. https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines9020099

Chicago/Turabian Style

Sellner, Johann, and Paulus S. Rommer 2021. "Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies" Vaccines 9, no. 2: 99. https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines9020099

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop